• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

H1 and CTI Partner for Clinical Trial Optimization

by Syed Hamza Sohail 12/11/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– H1, on a mission to connect the world to the right doctors, today announced a strategic partnership with CTI Clinical Trial & Consulting Services (CTI), a leading global full-spectrum research service provider. 

– Through this partnership, CTI will leverage H1’s Trial Landscape platform to drive data-informed clinical trial planning and execution to enhance strategic feasibility, real-world evidence, and clinical trial execution on a global scale. This integration bolsters efficiency and advances diversity, equity, and inclusion (DEI) initiatives in clinical trials, ultimately making research more representative and impactful.

CTI and H1 Partner to Enhance Clinical Trial Efficiency and Diversity

The collaboration between CTI Clinical Trial and Consulting Services (CTI) and H1 comes at a pivotal time for Contract Research Organizations (CROs), which face increasing complexity in analyzing diverse datasets across multiple indications and regions. By integrating H1’s Trial Landscape platform, a powerful AI-driven clinical trial data repository, CTI can streamline the analysis of patient demographics and treatment sites worldwide, optimizing study and research site strategies to focus on successful trial execution.

A primary objective of this partnership is advancing CTI’s commitment to FDA diversity guidelines. Using H1’s comprehensive data, CTI will craft detailed diversity action plans, identifying trial sites and principal investigators (PIs) with access to underrepresented patient populations. This approach ensures trials generate inclusive, representative data that enhance research quality, safety, and applicability.

The Trial Landscape platform supports all phases of the trial lifecycle:

  • Pre-award phase: Facilitates precise identification of sites and patients, a crucial factor in securing trial awards.
  • Post-award phase: Enhances timely and effective execution, meeting sponsor needs while improving global trial outcomes.

Earl Seltzer, Senior Director of Strategy & Innovation at CTI, emphasized the importance of the partnership: “We’re excited to collaborate with H1 and leverage the advanced capabilities of the Trial Landscape platform. This partnership not only boosts our operational efficiency but also reinforces our ability to deliver inclusive and impactful clinical trials that address the evolving needs of clients and patients across diverse therapeutic areas.”

By combining CTI’s expertise in trial management with H1’s advanced analytics, the partnership is set to redefine clinical trial operations, fostering inclusivity and delivering data-driven insights for better patient outcomes.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Clinical Trials

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |